Article
Association of the exon 3 deleted/full-length GHR polymorphism with recombinant growth hormone dose in growth hormone-deficient adults.
Pharmacogenomics - 1 Oct 2009
Meyer Silke, Schaefer Stephan, Stolk Lisette, Arp Pascal, Uitterlinden André G, Plöckinger Ursula, Stalla Günter K, Tuschy Ulrich, Weber Matthias M, Weise Alexander, Pfützner Andreas, Kann Peter H
Abstract excerpt
AIMS: Contradictory reports exist regarding the influence of the exon 3 deleted (d3)/full-length (fl) growth hormone receptor (GHR) polymorphism on responsiveness to recombinant human growth-hormone therapy in idiopathic short stature, small for gestational age and GH-deficient children, Turner syndrome patients and GH-deficient adults. In some of these studies, the d3 allele was associated with increased...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
